Market Overview
Global
Gastroenterology Market is forecasted to reach
USD 38.5 billion by the end of 2024 and grow to
USD 66.4 billion in 2033, with a
CAGR of 6.2%.
Gastroenterology is a medical specialty focused on the diagnosis, treatment, and prevention of diseases related to the digestive system, which includes the gastrointestinal (GI) tract, liver, pancreas, and gallbladder. It addresses conditions like acid reflux, ulcers, irritable bowel syndrome (IBS), Crohn’s disease, liver disorders, and cancers of the digestive organs. Gastroenterologists perform diagnostic procedures like endoscopies, colonoscopies, and biopsies to assess and manage these disorders.
The gastroenterology market is expanding primarily due to the increasing prevalence of gastrointestinal diseases. Additional key factors fueling this growth include the rise in gastrointestinal disorders linked to unhealthy dietary habits, the advancement of clinical trials with reliable results, increasing healthcare expenditure, and the aging population.
The US Gastroenterology Market
The US Gastroenterology Market is projected to reach USD 12.5 billion by the end of 2024 and grow substantially to an expected USD 20.5 billion market by 2033 at an anticipated CAGR of 5.8%.
The U.S. gastroenterology market is driven by the increasing cases of GI disorders including Crohn's disease, IBS, and colorectal cancer, an aging population, and growth in per capita healthcare expenditure, thereby boosting demand for advanced treatments.
Key trends within the gastroenterology market of the U.S. include increased application of biologics and biosimilars for the treatment of inflammatory bowel disease and Crohn's disease. Furthermore, genetic data and biomarkers in personalized medicine for developing treatment appropriate for individuals also became prevalent.
Key Takeaways
- Market Growth: The global gastroenterology market is projected to grow by USD 25.7 billion, with a CAGR of 6.2%.
- Market Definition: Gastroenterology is the branch of medicine focused on the digestive system, including the stomach, intestines, liver, and pancreas
- Type Analysis: Branded as a type is expected to dominate the gastroenterology market with the highest revenue share in 2024.
- By Route of Administration Analysis: Injectable is predicted to lead the gastroenterology market with the highest revenue share in 2024.
- Application Analysis: Crohn’s disease is predicted to dominate the gastroenterology market based on application with a high revenue share in 2024.
- End User Analysis: Retail pharmacies are predicted to dominate the gastroenterology market with the largest revenue share in 2024.
- Regional Analysis: North America is expected to lead the global Gastroenterology market with a market share of 38.6% by 2024.
Use Cases
- Diagnosis and Treatment: Gastroenterologists treat GERD (Gastroesophageal Reflux Disease), a chronic condition where stomach acid frequently flows back into the esophagus, causing heartburn and discomfort.
- Management of Inflammatory Bowel Disease: Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are chronic conditions that require ongoing gastroenterological care.
- Colorectal Cancer Screening: Gastroenterology is used in colorectal cancer screening through colonoscopy as regular screening is important for the early detection of polyps or cancerous growths in the colon, especially in high-risk individuals.
- Hepatitis and Liver Diseases: Gastroenterologists treat liver-related conditions such as hepatitis B and C, fatty liver disease, and cirrhosis. They conduct liver biopsies, imaging, and blood tests to monitor liver function and disease progression.
Market Dynamic
Drivers
Increasing Cases of Gastrointestinal DiseasesThe global rise in gastrointestinal conditions like, fissures, hemorrhoids, irritable bowel syndrome (IBS), gallstones, ulcerative colitis, and gastroesophageal reflux disease (GERD) is a significant driver of the gastroenterology market. The growing incidence of chronic and acute gastrointestinal illnesses is driven by factors like poor diet, sedentary lifestyles, stress, food sensitivities, & bacterial or viral infections which contribute to the growing incidence of both chronic & acute gastrointestinal illnesses.
Increasing Demand for Pharmaceuticals
The increasing cases of gastrointestinal disorders leads to increasing demand for various medications, including antacids, histamine H2-receptor antagonists, laxatives, proton pump inhibitors, and antibiotics. As healthcare professionals are searching to provide effective treatment options & prevent complications associated with these diseases, the market for pharmaceuticals targeting gastrointestinal ailments is expanding, which driving the growth of the market.
Restraints
High Cost of Endoscopy Devices
The increasing expense associated with endoscopy devices poses a considerable restraint on the growth of the global gastroenterology market. Essential equipment, like endoscopes, biopsy valves, polypectomy snares, clips, & balloon dilation systems, contributes to the overall high cost of endoscopy procedures, which limits the growth of the market.
Stringent Regulatory Frameworks
Stringent regulatory frameworks across the globe present another significant challenge for the gastroenterology market. Compliance with these regulations increases the financial burden on device manufacturers, leading to higher costs for endoscopy devices. This, in turn, affects the affordability of procedures for patients, particularly in developing nations with limited healthcare budgets.
Opportunities
Advancements in Personalized Medicine
The rise of personalized medicine shows a significant opportunity in the gastroenterology market, due to advancements in genomics and biotechnology. The treatments can be tailored to individual patients based on their genetic structure, lifestyle, & specific gastrointestinal conditions. This approach can lead to improved patient outcomes and reduced adverse effects, making personalized therapies a valuable area for investment and development.
Telemedicine and Digital Health Solutions
The increasing acceptance of telemedicine and digital health solutions offers a unique opportunity for gastroenterology practices. Remote consultations, digital monitoring, and mobile health applications can enhance patient engagement & accessibility, especially for those in remote areas. This shift not only expands the reach of gastroenterology services but also promotes better management of chronic conditions, leading to improved patient adherence and satisfaction.
Trends
Integration of Artificial Intelligence and Machine Learning
The integration of artificial intelligence and machine learning in gastroenterology is transforming the diagnosis and treatment approaches. AI-powered tools are being developed for endoscopic image analysis, predictive analytics for disease progression, & personalized treatment plans. It enhances clinical decision-making, & operational efficiencies within healthcare systems, which makes it a critical area of growth in the gastroenterology market.
Increasing Focus on Gut Microbiome Research
There is a growing interest in the role of the gut microbiome in gastrointestinal health and disease. There is much research on how gut bacteria influence conditions like obesity, diabetes, & inflammatory bowel diseases. This trend is leading to the development of probiotic and prebiotic therapies aimed at restoring healthy gut flora.
Research Scope and Analysis
By Type
Branded as a type is expected to dominate the gastroenterology market with the highest revenue share in 2024, due to the strong commercial success of branded gastrointestinal products, a promising investigational pipeline, and high product costs. Branded drugs are developed by companies which are investing heavily in research & development to create novel therapies. They often target specific and unmet medical needs in gastroenterology, like inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), & gastrointestinal cancers.
Clinical efficiency of these brands is strong along with robust marketing campaigns and physician loyalty to trusted brands, contributes to their dominance. On the other hand, the generic segment is expected to experience notable growth due to its significantly lower cost, which makes it more accessible to patients, especially in regions with cost-sensitive healthcare systems.
Moreover, the expiration of patents for several branded gastroenterology drugs has opened the door for generic manufacturers to produce cheaper alternatives, increasing their availability in the market. Government initiatives to promote the use of generics, as well as health insurance policies that encourage generic prescriptions, have further bolstered their adoption.
By Route of Administration
Injectable medications are expected to hold the highest revenue share in the gastroenterology market in 2024 due to their direct and immediate administration into bloodstream for therapeutic benefits. Remicade(r) can help manage symptoms associated with Crohn's disease, ulcerative colitis and certain liver disorders quickly and precisely to alleviate symptoms quickly while minimizing risks & potential complications. Please consult a healthcare provider prior to using.
It should never be administered or used unsupervised as described herein. Biologic therapies used for IBD treatment, like monoclonal antibodies used this way, must be given via injection as they cannot be effectively absorbed through the digestive tract if taken orally. Injectable medications typically offer greater bioavailability compared to oral ones, which may be partially broken down by stomach acids or enzymes before reaching their respective sites of action.
Precision, effectiveness and long-term disease management for advanced therapies in gastroenterology often requires intravenous administration; on the other hand, oral medication administration has grown increasingly popular due to convenience and patient adherence issues; oral medication may be preferred when treating less serious ailments like acid reflux, peptic ulcers or IBS.
By Application
Crohn’s disease is predicted to dominate the gastroenterology market based on application with a high revenue share in 2024. It is an inflammatory bowel disease that can affect any part of the gastrointestinal tract, leading to a range of symptoms including abdominal pain, severe diarrhea, fatigue, & weight loss. The rising condition of Crohn's disease led to increasing demand for effective treatments, which include biologics & immunosuppressive therapies.
Ongoing research into novel therapies & drugs aimed at managing Crohn's disease is contributing to its market prominence. The focus on personalized medicine and advancements in understanding the disease's pathophysiology is expected to further bolster the growth of this segment. Meanwhile, ulcerative colitis, which is characterized by chronic inflammation of the colon and rectum is predicted to show momentum.
The rising cases of ulcerative colitis is driving demand for treatment options, including corticosteroids, biologics, & new oral medications. This segment's growth is also supported by increasing awareness about the disease & advancements in therapeutic options.
By End User
Retail pharmacies are expected to dominate the gastroenterology market with the largest revenue share by 2024 due to their convenience for patients & widespread accessibility in urban & rural settings. Customers are now able to quickly fill prescriptions for common digestive ailments like acid reflux, irritable bowel syndrome (IBS), and Peptic Ulcers.
Pharmacy USA provides an assortment of medications used to address mild gastrointestinal symptoms and is frequently sought out as a source for immediate relief by those seeking quick relief from symptoms. These pharmacies provide customers with a personalized shopping experience where pharmacists provide expert guidance in using medications safely, helping build trust between themselves and customers and creating customer loyalty.
Pharmacy chains typically possess an advantage in serving gastroenterology patients due to their physical proximity and fast medication distribution services, giving them a competitive edge against independent pharmacies. Hospital pharmacies represent another key segment in the gastroenterology market as they play an essential role in treating complex or severe GI conditions like IBD, cancer of the digestive tract or liver disorders.
The Global Gastroenterology Market Report is segmented on the basis of the following
By Type
By Route of Administration
By Application
- Crohn's Disease
- Ulcerative Colitis
- GERD
- IBS
- Others
End User
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Regional Analysis
North America is expected to continue leading the gastroenterology market with a
share of 38.6% by 2024 due to technological advancement, lifestyle change diseases, aging and obese population, increasing research and development contributing to increased gastrointestinal disorder. Besides, key market players and government initiatives in the region for prevention and treatment of gastrointestinal disorder are expected to boost market growth.
In North America itself, there is the increased usage of advanced gastroenterology devices and equipment. High healthcare expenditure per capita and fairly good reimbursement policies prevailing in this region compared to other parts of the world are favorably impacting the growth of the market. Moreover, the US and Canada have the best-ranked medical institutions in the world. These countries have always been early adopters of most new lifesaving technologies. This has translated into a high demand for gastroenterology products that are newly developed.
The region also hosts numerous contract research organizations to facilitate clinical trials for newer devices, drugs, & techniques in gastroenterology. After North America, the Asia-Pacific region is expected to be the fastest-growing region owing to rapid economic growth in nations like China, India, & South Korea. It substantiates healthcare infrastructure and spending. Local manufacturers are also trying to engage in research and development to come up with low-cost devices that might meet regional demand. With that, international companies are expanding even further by partnering with local players to reach this lucrative market.
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The gastroenterology market is moderately fragmented, with several players competing for market share. To strengthen their positions, companies have increasingly adopted strategies focused on sustainable competition, such as developing new products and expanding their presence across regions and distribution channels. By introducing innovative treatments and broadening their geographic reach, these companies aim to capture a larger share of the market.
In addition to product and market expansion, companies are placing greater emphasis on optimizing supply chain management and improving operational efficiencies. Enhancing supply chain processes allows these players to reduce costs, streamline production, and ensure timely delivery of their products, which is crucial in maintaining a competitive edge. Some of the major companies in the gastroenterology market include Takeda Pharmaceutical Company, AbbVie, and Pfizer.
Some of the prominent players in the global gastroenterology market are
- AbbVie Inc.
- Allergan plc
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Eisai Co., Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis International AG
- Pfizer Inc.
- Procter & Gamble Co.
- Takeda Pharmaceutical Company Limited
- Other Key Players
Recent Development
- In August 23, 2024, Indian gastroenterologists launched the Gastro AI Academy to provide free AI education for GI physicians and surgeons, aiming to enhance patient care through advanced technology. FUJIFILM India partnered in this effort.
- In April 2024, OMNY Health collaborated with leading community-based gastroenterology practices and integrated delivery networks to introduce innovative real-world data solutions for research. This expansion added over 5,000 GI providers serving more than USD 10 million patients to OMNY's network, which now includes data from 380,000 providers and USD 75 million patients across the U.S. OMNY’s platform integrates de-identified EHRs to deliver insights into patient care, treatment outcomes, and social determinants, supporting large-scale, compliant research partnerships.
- In February 2024, Salvo Health, a gastrointestinal care startup, raised USD 5 million in Seed Prime funding led by City Light Capital and Human Ventures. The company, which operates a virtual care clinic for people with chronic gut conditions, intends to use the funds to expand its services and provider network.
- In March 2024, Johnson & Johnson submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA for TREMFYA's approval to treat adults with moderately to severely active ulcerative colitis (UC).
Report Details
| Report Characteristics |
| Market Size (2024) |
USD 38.5 Bn |
| Forecast Value (2033) |
USD 66.4 Bn |
| CAGR (2024-2033) |
6.2% |
| Historical Data |
2018 – 2023 |
| The US Market Size (2024) |
USD 12.5 Bn |
| Forecast Data |
2025 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Type (Branded, and Generics), By Route of Administration (Injectable, Oral, and Others), By Application (Crohn's Disease, Ulcerative Colitis, GERD, IBS, and Others), End User (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
AbbVie Inc., Allergan plc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eisai Co., Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis International AG, Pfizer Inc., Procter & Gamble Co., Takeda Pharmaceutical Company Limited, and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users) and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |
Frequently Asked Questions
The Global Gastroenterology Market size is estimated to have a value of USD 38.5 billion in 2024 and is expected to reach USD 66.4 billion by the end of 2033.
North America is expected to be the largest market share for the Global Gastroenterology Market with a share of about 38.6% in 2024.
Some of the major key players in the Global Gastroenterology Market are Takeda Pharmaceutical Company, AbbVie, and Pfizer. and many others.
The market is growing at a CAGR of 6.2 percent over the forecasted period.
The Global US Market size is estimated to have a value of USD 12.5 billion in 2024 and is expected to reach USD 20.5 billion by the end of 2033.